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Abstract. In this paper we address the complex and controversial issue of the possible commercialization of a 
genetically engineered (GE) salmon for human consumption: the AquAdvantage Salmon®, by one of the leading US 
aquaculture corporations, AquaBounty Technologies Inc (ABT). This analysis follows and deepens our reflections on 
the notion of impact assessment, in the framework of biotechnology for food production. In the first part, we 
consider the epistemic and normative implications involved in the regulatory process of the transgenic salmon, 
starting with a review of the scientific research on genetic engineering applied to the taxonomic family 
Salmonidae. We explore the inextricable relationship between facts and values, and their mutual dependence on 
the high stakes implied in the controversy. In the second part, we challenge the identification of impact 
assessment with future developments, the risks and promises of the GE salmon. We propose a shift to from 
prediction to diagnosis, and we provide a brief account of the driving forces that bring the transgenic fish into the 
world, along the path-dependent trajectory of technoscientific innovation. We conclude by proposing to open a 
collective space for reflection about the criteria for evaluating the quality of GE salmon in our present. 
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The word “impact” entails the idea that 
something is already into the world and it is 
“pressing” against a target1. In the still 
dominant, modern ideal, assessing the impact 
of technoscientific open-field 
experimentations means identifying the 
target and evaluating the consequences of 
this pressure, on the basis of scientific 
evidence collected by purposely-selected 
experts, for the needed regulatory aims. In 
this model, the certain, objective and 
exhaustive scientific evidence speak for 
themselves and rational decisions about the 
governance of technology can be made in the 
form of logical deductions (Wildavsky 1979). 
In our previous work, we have discussed 
some of the inadequacies of this framework 
in the context of biotechnology for food 
production (Benessia and Barbiero 2012, 
Guarnieri et al. 2008). By focusing on the 
research, implementation and regulation of 
genetically modified organisms in industrial 
agriculture, we have shown that this modern 
model can be applied only at the price of 
selectively obscuring the normative 
dimension inherent in the process of impact 
assessment. Indeed, the framing of what 
constitutes an evidence, the ways in which 
the designated significant data are collected 
and evaluated, the questions to be answered 
and the conclusions to be drawn are 
intrinsically value-based practices, embedded 
in the technical, scientific procedures. The 
needed expertise and the corresponding 
epistemic culture of the actual experts do not 
automatically emerge from a predefined 
laboratory setting in which the impact is set 
up to happen (Hardin 2004, Knorr Cetina 
                                                 
1
 The etymology of the term impact is to "press 
closely into something,": from Latin impactus, past 
participle of impingere "to push into, dash against, 
thrust at". Originally sense preserved in impacted 
teeth (1876). Sense of "strike forcefully against 
something" first recorded 1916. Figurative sense of 
"have a forceful effect on" is from 1935 (see online 
etymology dictionary www.etymnline.com). 
1999). They are the result of choices, based 
on specific aims, and they produce a plurality 
of perspectives, all valid in the context in 
which they emerge and most often mutually 
exclusive, therefore controversial (Sarewitz 
2004).  
Moreover, open field technoscientific 
experiments, such as GMO’s for food 
production, imply high stakes, as they require 
considerable investments, they are designed 
to be carried out on a global scale and, in case 
of failure, cannot be reversed. Finally, as they 
are performed on socio-ecological systems, 
including the agents performing them, they 
entail the presence of emergent complexity 
and radical uncertainty (Funtowicz and 
Ravetz 1994). As a result, in the evaluation of 
their impact, facts and values are inextricably 
entangled, uncertain and disputed, a 
condition that can be defined as post-normal 
(Funtowicz and Ravetz 1993). 
Based on these premises, in this paper we 
address the complex and controversial issue 
of the possible commercialization of a 
genetically engineered salmon for human 
consumption: the AquAdvantage Salmon®, 
by one of the leading US aquaculture 
corporations, AquaBounty Technologies Inc 
(ABT). According to ABT, through the 
addition of a growth-hormone gene construct, 
the patented fish is designed to reach the 
market size in about 18 months, close to half 
of the average time-to-market of 
conventionally farmed salmon. Moreover, the 
total feed required to produce the same fish 
biomass is reduced by 25%, giving the 
producer a significant net overall economic 
gain. As the AquaBounty narrative goes, this 
saving would make economically viable to 
rear the fish in otherwise too costly, 
physically contained inland facilities, isolated 
from marine ecosystems, therefore less 
polluting and more environmentally 
sustainable (AquaBounty Technology 2010).  
Over the past two decades, a number of 
different stakeholders, ranging from activists, 
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to concerned citizens and scientists, 
traditional fisheries and the aquaculture 
industry have been contesting these 
promised economic advantages and 
ecological benefits. At the same time, the 
environmental risks of genetic pollution of 
the wild salmon population and the possible 
hazards for human health have been widely 
discussed, prompting the need for precaution 
in the adoption of this new technological 
product. The scientific and political 
controversy around the AquAdvantage 
Salmon® has dominated the debate about the 
extension of genetic engineering from plants 
to animals, stalling the regulatory process and 
discouraging the research and development 
of other cases (Pollack 2012a).  
We consider here this exemplary case, in 
order to revisit and deepen our investigation 
on the notion of impact assessment, along 
two routes.  
In the first part, we consider the issue of 
scientific uncertainties and the normative 
implications, the complexity and controversy 
implicit in the impact assessment procedure. 
Indeed, as we will explicitly review, the 
research, implementation and 
commercialization of transgenic salmon 
involves a number of uncertain facts and 
contrasting values, concerning the definition, 
detection, measurement and evaluation of 
both the possible risks and the declared 
benefits.  
Moreover, the stakes are high; One the one 
hand the authorization for human 
consumption would constitute a precedent 
and open the doors to genetically engineered 
animals in food production systems, creating 
a whole new economy for industrial farming. 
On the other hand, the possible interactions 
of transgenic salmon with the wild species 
could induce irreversible damages to global 
marine ecosystems.  
Finally, even though the genetically 
engineered salmon has been under the 
attention and then the review of the US Food 
and Drug Administration (FDA) since 1995, 
the regulatory, decision-making process is 
embedded in a narrative of urgency. As we 
will explore, the global growing need for 
animal protein, the raising concerns about 
ocean degradation and depletion, the US 
seafood trade deficit and the possible 
competitive disadvantage with other 
countries eventually ahead in the market of 
transgenic animal food, are some of the main 
arguments in favor of a fast and effective 
approval of the AquAdvantage salmon in the 
US. Ultimately, and way more specifically, the 
financial survival of AquaBounty 
Technologies itself is at stake in the waiting.  
This narrative of urgency will be explored in 
the second part of the paper, where we 
extend our analysis by concentrating on the 
logically former, fundamental premise of the 
whole framework of analysis, namely the 
strong and implicit normative stance 
according to which we identify impact 
evaluation with future developments. 
 This assumption is the grounding pillar of the 
modern principle of responsibility, according 
to which we need to predict the future in 
order to justify our action in the present 
(Jonas 1985). If we follow these premises, we 
are lead to paradoxical situation in which we 
need to know about the future consequences 
of our implementation in order to act, but we 
are prevented from knowing the future 
developments, as a consequence of the 
intrinsic nature of the very same 
implementation (Benessia et al., 2012). A way 
out of this inherent contradiction is to shift 
our attention back to the present and to 
divert our analytical and reflective capacity 
from prediction to diagnose and from 
responsibility under risk to commitment in 
times of change (Funtowicz and Strand 
2011).  
The idea is then to divert our focus from the 
possible targets and the consequences of the 
impact, to the impacting object itself, 
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considering the driving forces that bring it 
into being and determine its trajectory. In 
other words, we propose to suspend for a 
moment the scenario of the future 
developments, risks and promises, and ask in 
what kind of world this technoscientific 
product - a genetically engineered, fast-
growing salmon - has a meaning that justifies 
the scientific and economic effort of actually 
fabricating it, proposing to sell it and being 
confident that someone will buy it. These 
issues have to do with how we collectively 
value the salmon at stake and therefore with 
it’s quality: as a living being embedded into a 
net of socio-ecological systems, as a 
technoscientific commodity, and as food.  
As we will see, in this framework, the 
AquAdvantage salmon can be interpreted as a 
belonging to the path-dependent trajectory of 
technoscientific innovation and its main 
drivers of optimization and substitution 
(Benessia and Funtowicz 2015).  
With these elements in mind, let’s begin our 
investigation with the scientific uncertainty 
and disputed values embedded in the 
research and implementation of genetically 
engineered salmon. 
2. GE salmon: scientific uncertainties 
and normative implications  
As any other technoscientific product, GE 
salmon depend on scientific research in at 
least three ways: for its production, impact 
evaluation and regulation. Accordingly, 
different epistemic and normative cultures, 
modes of analysis and decision-making 
praxes can be applied to its implementation 
and regulation. More specifically, as we have 
extensively developed in our previous work 
(Benessia and Barbiero 2012), both the 
production and the regulation are driven by 
the epistemic culture of innovation2, whereas 
                                                 
2
 Innovation science (Wynne quoted by Jasanoff, 
2005) is typically carried out by private industries, 
not rarely granted with public funds (Goldenberg 
the impact evaluation can and should be 
conducted by focusing on the so-called 
negative or liminal knowledge (Kastenhofer 
2007, Knorr Cetina 1999) within the 
epistemic culture of precautionary science3, 
in order to deconstruct the main pillars of the 
innovation approach and leave room for a 
democratized, post-normal evaluation of 
biotechnology applied to aquaculture. In what 
follows, we will start by reviewing the main 
results emerging from the scientific literature 
regarding the research behind the production 
of the AquaBounty GE salmon. We will then 
move to the complexity and controversy 
inherent in its possible commercialization. 
                                                                         
2011), with the explicit aim of developing and 
introducing new (bio)technological products in the 
market. The prevalent goal of this type of endeavor is 
to make things work. This, in turn, entails a 
methodology founded on laboratory trial-and-error 
iterative approximation to the desired result, through 
the design and management of linear cause-effect 
relationships between a limited or limitable number 
of variables (i.e. a specific gene for a specific 
property, according the central dogma ideal which we 
will discuss in the following section). The 
corresponding epistemic culture of innovation 
science is therefore essentially based on determinism, 
reductionism and mechanism, applied in vitro, to 
small and de-contextualized temporal and spatial 
horizons, and resulting in the production of so-called 
hard facts, namely new goods, characterized by a 




 Precautionary science (Ravetz, 2004) is normally 
undertaken within research institutions such as 
universities, and it involves the understanding and the 
management of the consequences of large-scale 
techno-scientific implementation. Its main focus is 
therefore the complexity of interaction between the 
organisms involved – conceived and treated as 
processes – and the environment. The correlated 
epistemic culture of this type of scientific research is 
based on observation in situ, through systemic 
approaches over large population systems and 
extended temporal and spatial horizons, involving 
highly non-linear causal links, such as retroaction 
mechanisms, dependence on initial conditions etc. 
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Salmon are osteichthyes belonging to the 
taxonomic family Salmonidae and they are 
divided into two genera: Oncorhynchus, 
which includes 14 species of salmon and 
trout that live in the Pacific Ocean, and Salmo, 
which includes 29 species of salmon and 
trout that live in the Atlantic Ocean. The most 
widely studied genetically modified salmon is 
the transgenic Coho salmon (Oncorhynchus 
kisutch), into which the promoter region4  of 
a gene regulator controlling the expression of 
the growth hormone (GH) gene has been 
inserted. The promoter is directly inserted 
into fertilized eggs using a vector. Since the 
fertilization and development of fish eggs 
occurs externally, no process of internal re-
implantation is necessary. Once the females 
have spawned, their eggs can be collected and 
subsequently fertilized without any apparent 
effects upon the development of the salmon 
fry (Fletcher and Davies 1991). GH stimulates 
cell division, muscular and skeletal growth, 
the hepatic production of insulin-like growth 
factor (IGF) and the immune system. The 
production of GH is, in turn, inhibited by the 
presence of glucocorticoids, which have an 
anti-inflammatory function, and by 
somatostatin, which inhibits the production 
of insulin. In addition to Coho salmon, other 
species of salmon have been engineered to 
overexpress GH, including the Cherry salmon 
(Oncorhynchus masou) and, as we will see, 
the Atlantic salmon (Salmo salar). 
2.1 Physiopathology of GE salmon 
An analysis of the literature offers a 
fragmented view of the physiology of 
genetically modified salmon: studies have 
been conducted on different Salmoninae 
subfamily species using different 
methodologies and with different research 
objectives. It is therefore difficult to delineate 
a coherent overall picture. Nevertheless, it 
appears clear that genetically modified 
salmon, independent of the originating 
                                                 
4
 Originating from the Sockeye salmon, 
Oncorhynchus nerka. 
species, differ from corresponding non-
transgenic on at least three levels: growth, 
deregulation of the GH axis, and reproduction.  
2.1.1 Growth 
The most studied species of salmon that has 
been genetically modified to continually 
produce GH is the Coho salmon 
(Oncorhynchus kisutch). This transgenic 
salmon grows at a faster rate than non-
transgenic Coho salmon as a result of its 
greater consumption of food (Sundström et 
al. 2005). Six months post hatching, 
genetically modified Coho salmon reach the 
weight and degree of coloration that non-
transgenic Coho salmon achieve after 24 
months (Devlin et al. 2004). When fed 
identical quantities of food, genetically 
modified Coho salmon do not grow faster 
than their non-transgenic homologues 
(Stevens and Devlin 2005). Furthermore, if 
farmed with insufficient access to food, 
fitness levels in the transgenic Coho salmon 
are drastically reduced compared to those of 
non-transgenic Coho salmon farmed under 
the same conditions, which instead adapt 
better to conditions of food insufficiency 
(Delvin et al. 2004). 
A more in depth study was performed on 
Atlantic salmon (Salmo salar) by Deitsch and 
colleagues (2006). As for Coho salmon, 
transgenic Atlantic salmon grow quicker than 
non-transgenic salmon of the same species: 
transgenic Atlantic salmon achieve a body 
mass index (BMI) that is 21-25% greater than 
that of the non-transgenic ones. However, as 
expected, oxygen consumption is unchanged 
in transgenic Atlantic salmon compared to 
the non-transgenic, as the gill surface area is 
not influenced by GH activity. Whatever the 
cause, transgenic Salmon grow to become 
much bigger fish, although much less efficient. 
Transgenic Atlantic salmon have a metabolic 
rate that is 18% lower and a critical 
swimming speed that is 9% slower than non-
transgenic. On the other hand, transgenic 
Atlantic salmon possess a cardiac volume that 
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is 29% larger, a cardiac output that is 18% 
greater and a post-stress blood hemoglobin 
concentration that is 14% higher than that of 
non-transgenic homologues. These 
physiological modifications, associated with 
significant anatomical aberrations in 
transgenic salmon, may represent 
adaptations resulting from the excessive 
strain placed upon the fish’s metabolic 
system. This, in turn, might have a negative 
impact upon swimming performance (Hu et 
al. 2010). 
Thyroid function plays a key role in growth. 
In a study conducted to investigate thyroid 
function in relation to salmon growth, Eales 
and colleagues (2004) considered three 
groups of Coho salmon: non-transgenic 
salmon fed to satiation (NTS), transgenic 
salmon fed to satiation (TS) and transgenic 
salmon fed the same ratio of food consumed 
by the non-transgenic salmon (TNT). As 
expected, the TS group grew twice as fast as 
NTS and TNT fish. Eales and colleagues then 
evaluated the plasma concentration of the 
thyroid hormones T3 and T4. While no 
differences were found in T4 concentrations 
between the three groups, greater plasma 
concentrations of T3 were found in the 
transgenic salmon (TS and TNT) with respect 
to non-transgenic. At the same time, the 
activity of T3 (and T4) in the liver was less in 
the transgenic salmon (TS and TNT). Thus it 
seems that the plasma concentrations of T3 
and T4 and their hepatic activities depend 
directly on the expression of GH and not on 
the quantity of food available.  
2.1.2 Biochemical alterations caused by 
deregulated GH expression  
In order to understand the chronic effects of 
the deregulated expression of GH, it is 
necessary to analyze the complex cascades of 
intra- and intercellular biochemical reactions. 
Although non-exhaustive, some lines of 
experimental evidence provide important 
information. For example, a study conducted 
on the expression of hepatic genes in 
transgenic Cherry salmon (Oncorhynchus 
masou) revealed that the mRNA expression 
levels of the following proteins are all 
increased in these fishes: the enzyme haeme 
oxygenase; leukocyte cell-derived chemotaxin 
(LECT2); α-trypsin inhibitors; proteins linked 
to iron metabolism; and proteins linked to the 
reproductive system. On the other hand, the 
expression of lectin, D-6-desaturase, 
apolipoprotein and pentraxin were reduced 
in transgenic Cherry salmon. Pentraxin is 
involved in a specific immune processes, 
which appear to be weakened in second (F2) 
and third (F3) generations of transgenic 
Cherry salmon (Mori et al. 2007). In another 
study conducted on transgenic Coho salmon 
fed to satiation, increases were detected in: 
tissue levels of glutathione – a tripeptide that 
performs important antioxidant functions; 
glutathione reductase activity – which 
catalyzes the formation of glutathione 
disulfide; and γ-glutamiltranspeptidasi 
activity in the intestine – an enzyme critical 
for the catabolism of glutathione (Leggat, et 
al. 2007). However, all values lay within 
normal ranges if food ratio were restricted, 
demonstrating that the regulation of the 
antioxidant system is linked to accelerated 
growth and not to the direct activity of the 
transgene. 
2.1.3 Reproduction 
The reproductive behaviors of transgenic 
Coho salmon have been studied in relation to 
the ecological consequences of their 
interaction with wild Coho salmon in natural 
habitats. Bessey and colleagues (2004) 
observed that transgenic Coho salmon are 
able to mate with their non-transgenic 
homologues and give rise to fertile offspring. 
Transgenic Coho salmon reach sexual 
maturity at around 2-3 years of age – 
extremely early compared to non-transgenic 
Coho salmon that instead require 4-5 years. 
Female transgenic Coho salmon appear to be 
more fertile, even though they display less 
courtship behavior and produce fewer eggs of 
smaller dimensions compared to non-
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transgenic females in the wild. Transgenic 
male Coho salmon do not differ from the non-
transgenic males with regard to the 
production of gametes and courtship 
behavior in non-competitive conditions; but 
in competitive conditions, the transgenic 
males also display less courtship behavior. 
2.2 Ecology 
The second line of investigation is focused on 
the ecological impact of genetically modified 
salmon: i.e. the study of the relationships 
between the communities of genetically 
modified and wild (non-transgenic) salmon. 
Two issues constitute the heart of the debate: 
does the presence of the transgene change 
the reproductive fitness of transgenic salmon 
compared to that of wild salmon? And, what 
happens if a transgenic salmon mixes with a 
population of wild salmon? Three main areas 
of experimental investigation can thus be 
defined: (1) the potential competition 
between genetically modified and wild 
salmon populations; (2) the possible transfer 
of the transgene into the wild salmon 
population; and (3) the evaluation of the 
predatory behavior expressed by genetically 
modified salmon towards their non-
transgenic homologues.  
As the evaluation of reproductive fitness in 
natural environments is difficult to evaluate 
experimentally, several theoretical models 
have been developed. One of the most 
interesting model is the one proposed by 
Muir and Howard (1999) who coined the 
concept of the “Trojan Gene Effect”.  The two 
scientists from Purdue University posit that 
when a transgene confers a survival 
disadvantage while at the same time a mating 
advantage, the mating advantage would drive 
the transgene into a natural population while 
the survival disadvantage would cause 
population numbers to gradually spiral 
downward and eventually result in local 
extinction of the wild population. In another 
theoretical model, the increase in the 
frequency of the transgenic genotype 
corresponds with a reduction in the 
reproductive fitness of the wild population 
(Hendrick, 2001). Together, these models 
highlight the fact that the simple introduction 
of a genetically modified salmon into a 
natural environment, independent of its 
relative reproductive fitness that may be 
greater or less than that of the wild 
homologue, increases the risk of extinction of 
the wild species. 
It is also interesting to note the observations 
of Devlin and colleagues (2004): according to 
these authors, when transgenic Coho salmon 
are farmed in the same tank as their non-
transgenic homologues with an abundance of 
food available, the fish develop without 
interfering with each other. However, when 
farmed under conditions of limited food 
resources, the transgenic Coho salmon adopt 
more aggressive behaviors, expressing 
dominance over the non-transgenic and 
interfering with the latter’s growth to the 
extent that the GM fish may start to hunt and 
feed upon the smaller non-transgenic salmon; 
thus leading both populations towards 
extinction. Under the same food shortage 
conditions, the non-transgenic salmon farmed 
alone would have survived without any 
particular problem. Although it is difficult to 
establish conditions of food “shortage” or 
“abundance” in a natural environment, 
concerns remain relative to the danger 
represented by the accidental introduction of 
transgenic Coho salmon into a population of 
wild Coho salmon. 
Overall, these studies seem to highlight a 
recurrent theme within the realm of ecology: 
even minimal variations in baseline 
conditions can result in very different results, 
making studies difficult to compare. It is 
therefore difficult to evaluate experimentally 
the risk associated with the introduction of 
GM salmon into aquatic ecosystems. 
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2.3. Towards the commercialization of GE 
salmon  
When leaving the realm of research and 
stepping into the actual industrial production 
of a patented GE salmon for a possible 
commercial use, the reductionist framework 
of innovation and regulatory science clashes 
inevitably against the precautionary 
approach of ecology and physiology. The 
issues that we have explored so far become 
then inevitably controversial, facts and values 
entangled. Let’s see how. 
As we have mentioned, AquAdvantage 
Salmon is the trade name of the genetically 
modified Atlantic salmon created by 
AquaBounty Technologies Inc. (ABT). 
AquAdvantage Salmon contains a genetic 
construct made by the promoter and the 
terminal region of an antifreeze gene 
extracted from the Ocean Pout (Zoarces 
americanus) genome and the growth 
hormone (GH) regulating gene from Chinook 
salmon (Oncorhynchus tshawytscha). In non-
transgenic salmon, the gene promoter that 
regulates the production of GH is only 
expressed in response to specific 
environmental stimuli, including temperature 
and the duration of daytime light (Bjornsson 
1997), while the promoter in genetically 
modified salmon is constantly active (Devlin 
et al. 1995). As gene expression systems are 
regulated by negative feedback, it is clear that 
the choice of a promoter obtained from a 
species that does not belong to Salmonidae 
was aimed at preventing the action of the 
growth regulators in Atlantic salmon; thus 
isolating the system that produces GM from 
the salmon’s own physiology5. GH in Atlantic 
salmon is very similar to that of Chinook 
salmon, although not identical. The mRNA 
nucleotide sequences of the two GH genes 
possess 90% homology (1013/1126 
                                                 
5
 On the other hand, the choice of an Oncorhynchus 
is not necessary from the biological point of view, 
but it becomes essential to provide the transgenic fish 
with a more reassuring identity as a “natural” fish. 
nucleotides). A comparison of the protein 
sequences found that 198/210 of the amino 
acids were identical, 7/210 of the amino acids 
were similar, but 5/210 amino acids were 
effectively different (Bodnar 2010)6. The 
process of integrating the genetic construct – 
called EO-1α – resulted in the rearrangement 
of the promoter that reduced its potential 
expression. This transgenic salmon was then 
crossed with a non-transgenic Atlantic 
salmon and the EO-1α genetic construct was 
found to be stable in second (F2) and fourth 
(F4) generations (Yaskowiak 2006).  
Female AquAdvantage Salmon homozygous 
for the EO-1α genetic construct are induced 
to transform into males (neomales) by 
treatment with 17-methyltestosterone. The 
male gametes produced (which do not 
contain male chromosomes, however, being 
derived from female chromosomes) are used 
to fertilize the eggs produced by non-
transgenic salmon. In this way, all new-born 
are female and possess a copy of the EO-1α 
gene (Bodnar 2010) .  
The data made available by ABT indicate that 
AquAdvantage Salmon grow in body weight 
approximately 2 times faster than non-
transgenic Atlantic salmon and its feed 
conversion rate is about 10% lower than 
conventional salmon (AquaBounty 
Technology 2010). The idea is then to 
develop a fish product that is substantially 
equivalent to its wild type counterpart, but it 
is functionally different, namely more 
efficient, as it requires less time to grow and 
be ready for the market. 
2.3.1. Growth rate and the standard Atlantic 
salmon 
The official picture of the AquAdvantage 
salmon portrays two fish swimming in crystal 
clear waters over artificially blue pebbles, 
                                                 
6
 This sex-reversal technique is a common practice in 
trout farming, as female grow faster and with has 
higher quality flesh (Dunham 2011). 
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side by side. They both look alike except the 
one is double the size of the other7. The 
image, first publicized by ABT itself and then 
filtered through all scientific and popular 
media, is meant to represent the difference in 
size – and size only – of two salmon of the 
same age, about 10 to 12 months old. In other 
words, it represents a growth rate and not the 
end state of development. The intrinsic 
ambiguity of the picture evokes ABT constant 
need to reassure the public of the fact the 
actual size of its trademarked salmon is not 
out of proportion when maturing and 
entering into the market. An overall larger 
size would indeed foster the stigma of 
abnormality associated with the GE fish and, 
even more importantly, raise ecological 
concerns about a possible mating advantage 
of the transgenic salmon over smaller non-
transgenic populations8.  
If the identity of the bigger fish – the GE 
salmon – is unequivocal, the other – the non-
transgenic, standard comparator – is highly 
controversial. The technical-scientific 
counterpart of this photograph is the ABT 
growth diagram presented in the regulatory 
submission to the FDA, where weight is 
measured as a function of time (Aquabounty 
Technology 2010). There, we see the 
AquAdvantage growth curve comfortably 
above an unspecified “Standard Salmon” size 
development. The issue is to define what a 
“standard” farmed Atlantic salmon actually is. 
Indeed, different strains of salmon do not 
grow alike, and the traditional breeding 
technology has made enormous progress in 
optimizing growth-rates. In 2011, Norwegian 
grower Salmonbreed issued a press release 
showing that its own (non-transgenic) 
salmon grow as fast or faster than ABT 
salmon. In the document, within the same 
kind of diagram, the Salmonbreed growth 
curves are comparable or higher than the 
                                                 
7
 See http://aquabounty.com. 
8
 Published studies report that, in some cases, 
transgenic fish do not only grow faster, but also reach 
a larger size (de la Fuente et al. 1999). 
AquAdvantage salmon (Salmonbreed 2011). 
More recently, a governmental Canadian risk 
assessment draft review casted further 
doubts about the accelerated growth rates of 
the GE salmon (Colwell 2015, Department of 
Fisheries and Oceans Canada 2013). 
What is presented as an objective and certain 
scientific assertion becomes inevitably 
questionable - and it is questioned - when the 
stakes associated with the assertion begin to 
grow. In this case the European salmon 
farmers and breeders, particularly the 
Norwegian who dominate the aquaculture 
industry, a sector that globally amounts to a 
business of $107 billion-a-year, obviously 
look at the possible emergence of a US GE 
salmon into the international market with 
careful and competitive attention (Gibbs 
2011).  
 
2.3.2 Physiopathological problems and the 
data controversy 
In a report addressed to the Center for 
Veterinary Medicine of the U.S. Food and 
Drug Administration (CVM-FDA), ABT 
acknowledges that the first generations of 
AquAdvantage Salmon exhibited a high rate 
of malformations, although they then 
underline that after ten years of crosses “the 
health and well-being” of AquAdvantage 
Salmon does not differ from that of non-
transgenic Atlantic salmon (AquaBounty 
Technology 2010). However, no scientific 
explanation of this phenomenon is supplied. 
The Veterinary Medicine Advisory Committee  
(VMAC) seemed to be surprised, above all 
because “the decrease in irregularities was 
not as notable in non-GE comparators”, but 
they then concluded that “it may be a function 
of the underlying genetics of the brood stock 
families used in the breeding crosses, or 
possibly, other factors” (VMAC 2010, p. 29). It 
would be interesting to know what these 
“other factors” are, as the data arising from 
only five years of investigation were 
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considered and, above all, the trend in the 
values of malformations seems to be random: 
for example, in the final year of analysis, the 
percentage of non-transgenic salmon, used as 
controls, presenting malformations was equal 
to 71.5% (Table 4, p. 28), a surprisingly high 
value.  
In addition, a more complete understanding 
of animal physiopathological issues is 
problematic, as a consequence of the 
standard culling practice for selectively 
improving the brood stock and optimize the 
use of available space, the AquaBounty data 
about physiopathological problems were 
inherently biased (FDA–VMAC 2010 p.26). 
This issue has been acknowledged by the 
VMAC and the FDA suggested implementing 
“post-approval safety surveillance” measures, 
applying a controversial post-market 
regulatory approach (FDA–VMAC 2010 p.60, 
Development Fund 2013).   
Finally, until ABT releases the experimental 
protocols about the growth of the 
AquAdvantage salmon, the only possibility for 
independent researchers is to extract 
inferential data from similarly engineered 
species. And, as we have seen, the available 
data indicate: 1) serious skeletal and 
muscular malformations that can 
compromise the swimming performance of 
the fish (Lee et. al. 2003) 2) un-synchronic 
growth of the skeleton-muscular apparatus 
with respect to the cardio-breathing 
apparatus, which can even kill the fish for 
suffocation (Deitch et al. 2006) 3) hormonal 
dysfunctions, in particular regarding the 
thyroid gland, which regulates the overall 
metabolism of the organism (Eales et al. 
2004).  
2.3.3. Ecological problems and the narrative of 
control 
Currently, ABT produces GE salmon eggs in 
its facility in Saint Prince Island, Canada and 
then fly them to another facility in Boquete, 
Panama where the salmon are grown to 
market size. The plan is then to ship the final 
fish product to the United States for 
consumption. This quite impractical 
geographical and logistic configuration has a 
specific history.  
In 1995, when E/F Protein – the early name 
of today AquaBounty - first applied to the U.S. 
Food and Drug Administration to regulate its 
product, the AquAdvantage salmon was 
meant to occupy a (possibly advantageous) 
place into the conventional open-water net-
pen marine aquaculture industry (Bratsbies 
2008). The life of this business plan was 
meant to be short.  
As transgenic salmon can mate and give rise 
to fertile offspring, in the late nineties, raising 
concerns about the environmental risks of GE 
escapees into open waters prompted the 
North Atlantic Salmon Conservation 
Organization (NASCO) to issue specific 
guidelines directing that aquaculture of 
transgenic salmon occurred only in self-
contained, land-based facilities (NASCO 1997) 
and enacted an agreement to adopt a 
precautionary approach to the possible 
implementation of GE salmon aquaculture 
(NASCO 1998). In 2002, the National 
Research Council also called for caution in 
experimentation and commercialization of 
transgenic fish (NRC 2002). The open 
questions of gene transfer and possible 
genetic invasion of the transgenic species, 
fostered by the formulation of the Trojan-
Gene Effect by Muir and Howard in 1999, 
fuelled vigorous objections to the possible 
commercialization of GE salmon by a number 
of NGOs and other representative of the civil 
society, such as the Union of Concerned 
Scientists, calling for more information and 
research given the many unknowns of this 
open field experimentation (UCS 2001). In 
2003, this overall climate lead NASCO to issue 
a resolution terming transgenic salmon as 
“high risk” and proposing a set of guidelines 
to direct member states to “take all possible 
actions to ensure that the use of transgenic 
salmon, in any part of the NASCO Convention 
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Area, is confined to secure, self-contained, 
land-based facilities” (NASCO 2003).  
Given the broad and raising agreement about 
the potential risks of GE salmon joining the 
vast crowds of escapees from conventional 
open water net-pen aquaculture (Gausen and 
Moen 1991, McKinnell et al. 1997 and Crozier 
1998), and the consequent lowering 
probability of approval from the FDA, 
AquAbounty modified its business plan, 
abandoning the idea of conventional open sea 
facilities and moving towards the idea of self-
contained, land-based aquaculture. From then 
on, with a quite brilliant marketing shift, the 
GE salmon became the only solution to make 
this highly expensive and less polluting fish 
farming technique economically feasible.  
A new facility was established in 2007 in the 
remote Panamanian location of Boquete, on 
the banks of the Calderas river in the western 
highlands of Chiriqui province. The choice of 
the place was never commented by ABT, if 
not on the grounds of being a highly hostile 
environment for possible escaped salmon. 
Indeed the water temperature of the nearby 
canals is high enough to jeopardize the 
survival of a GE salmon, and the closest sea is 
the Pacific ocean, where AquAdvantage 
Atlantic salmon would have no chance to 
reproduce, given that Atlantic and Pacific 
salmon don’t interbreed9 (Bodnar 2010).  
Established in 1996, the hatchery in Saint 
Prince Island is also self-contained. Although 
the fresh watercourses in Eastern Canada 
have been historically one of the natural 
habitats of Atlantic salmon, their current 
degradation due to acid rain and the 
installation of physical barriers make them an 
                                                 
9
 Commentators suggest that ABT moved to Panama 
for its less regulated approach to biotechnology. 
Indeed, if the GE salmon they are grown outside of 
the United States, AquaBounty does not have to 
complete a full Environmental Impact Statement as 
required by the Environmental Protection Agency 
(Greenberg 2010). 
unfriendly environment to salmon escapees 
(Bodnar 2010). 
Following a narrative of control (Benessia 
and Barbiero 2012), in addition to these 
environmental barriers, ABT implemented a 
number of containment strategies within its 
facilities. The first barrier is biological, 
consisting on farming only sterile female 
salmon. Sterility occurs due to the fact that 
these salmon are made triploid, i.e they 
contain three copies of each chromosome, 
instead of the usual two copies (diploid). 
Crucially in this context, triploid fish do not 
produce gametes. The most common method 
used to create triploid fish is to expose the 
eggs to a pressure shock treatment. This 
causes the retention of the second polar body 
and the eggs thereby retain their 
chromosome complement (Benfey et al. 
1988). However, triploid fish develop more 
slowly (Devlin et al. 2004) and exhibit a 
higher probability of manifesting aberrant 
phenotypes (VMAC 2010), but this seems to 
be the price that the industry is willing to pay 
in order to guarantee the sterility of farmed 
salmon. 
Moreover, and quite significantly in this 
scenario, sterility is never complete (Devlin 
2010). This procedure has a success rate 
equal to 98.9% in the ABT laboratories, with 
1.1% of eggs remaining diploid. An open 
concern about this issue emerges in the 
report by ABT: “the acceptance criterion is 
such that the likelihood of releasing a batch of 
eyed-eggs that are not at least 95% triploid is 
less than 0.05. Individual upwelling chambers 
that fail to meet test criteria will be re-tested 
and destroyed upon confirmed failure” 
(AquaBounty Technology 2010, p. 61). 
Confirming the lack of reliability of the 
proposed sterilization procedure, in 2011, the 
US Department of Agriculture granted the 
company a controversial funding of about half 
a million dollars to improve ABT biological 
containment technologies (USDA 2011). 
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Finally, the physical containment consists on 
an elaborate series of measures, leading the 
ABT CEO Roy Scotish to define its facilities as 
“aquatic Forth Knox” (Henry 2014). Indeed, 
ABT isolates its structures through the use of 
security enclosures, the use of 24-hour 
surveillance guards assisted by security 
cameras, the implementation of a series of 
filters, nets and other containment systems, 
and the sterilization of the egg production 
plant drainage areas using chlorine to kill 
eggs that escape filters (Bodnar 2010).  
The risk of harm from GE animals is defined 
in the regulatory framework as the product of 
(a) harm, given exposure to the hazard (i.e. 
the GE animal) and (b) the probability of 
exposure. By focusing on the reduction of the 
probability of exposure, with its redundancy 
of biological, environmental and physical 
security measures, ABT has obtained a 
favorable environmental assessment from the 
FDA in 2013, with a “finding of no significant 
impact” (FDA 2013).  
William R. Muir, one of the authors of the 
well-known work on the “Trojan gene effect”, 
presented his own favorable scientific-based 
opinion in a VMAC public meeting, hosted by 
the FDA in September 2010 (Muir 2013). In 
his talk, he explained why the AquAdvantage 
salmon would not be a plausible carrier of a 
Trojan gene, thus presenting “little or no 
environmental risk” of genetic spread, 
quoting among others, the work of Moreau 
and colleagues. In this paper, published in 
2011, the authors conclude that: “Although 
transgenic males displayed reduced breeding 
performance relative to non transgenic ones, 
both male reproductive phenotypes 
demonstrated the ability to participate in 
natural spawning events and thus have the 
potential to contribute genes to subsequent 
generation" (Moreau et al. 2011). The search 
for liminal knowledge that characterizes the 
epistemic culture of precautionary science is 
measured up against the more pragmatic 
need for certainty of regulatory science: what 
constitutes a little – essentially not 
measurable – risk of genetic spread, becomes 
not significant in the hands of a scientific 
advisor called to regulate a product of 
technoscientific innovation10.  
In the second part of its report, Muir 
presented “theory and data concluding that 
conventional farming of salmon in net pens is 
potentially more harmful than GE salmon due 
to competition and genetic load issues” (Muir 
2013). His rationale for comparing the two 
distinct cases is justified by the fact that, in 
his words, “there is no such thing as zero 
risks and all risks are relative to an 
alternative” (Muir 2013). In analogy with the 
purported benefits of AquAdvantage salmon 
– namely its growth rate – the objectivity 
inherent in the choice of the relative risk 
comparator is questionable. More specifically, 
the idea that the two options are mutually 
exclusive and they are the only available 
possibilities is the result of a specific implicit 
framing of the issue at stake. As we will see, 
the more likely scenario in case of approval is 
that both products (GE salmon produced 
inland and non-GE salmon produced in open 
waters) are available and competing on the 
market. 
Moreover, in this approach to risk 
assessment, the kind of farmed fish (i.e. the 
                                                 
10
 In addition to the concerns related to the impact on 
the genetic makeup of wild salmon populations of a 
Trojan Gene, escaping GE populations might also 
adversely affect other native fish, invading their 
niches. In a recent article, scientists from Canada 
have found that transgenic Atlantic salmon can cross-
breed with the brown trout, a closely related species 
(Oke et al. 2013). Even sterile GE fish may pose 
problems to wild populations, as escaped transgenic 
fish would still engage in courtship and spawning 
behaviour that could disrupt breeding in wild 
populations and decrease overall reproductive 
success. Also, even without exhibiting any 
reproductive behaviour at all, escaped sterile fish 
could still create ecological interference by simply 
competing with wild fish. In this overall scenario, the 
presence of radical uncertainty and unknown 
unknowns cannot be ruled out (Kapucinsky in Palca 
2011). 
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harm factor) and the facilities in which they 
are raised (i.e. the probability of exposure) 
are intertwined: when compared to the highly 
vulnerable conventional aquaculture net-
pens, in direct contact with open waters and 
prone to the attack of predators and extreme 
weather events, the ABT actual aquatic Fort 
Knox-types facilities are predictably less 
exposed to a risk of breakdown. On the other 
hand, the risk of escaped non-transgenic 
salmon compromising the wild populations 
relative to the one of escaped GE salmon is 
essentially skewed towards the latter: this is 
the reason why, as we have seen, 
conventional aquaculture of GE salmon has 
been classified as “high risk” by NASCO in 
200311. Clearly, then, the safest way to farm 
GE salmon is inland, but the optimal solution 
in terms of relative risks would be to raise 
non-GE salmon under the same conditions, 
requiring less security measures. When 
combined with the dispute about the actual 
growth rate of non-transgenic salmon, the 
debate about relative risk and benefits 
becomes inevitably complex and 
controversial. 
Finally, in terms of absolute, cumulative risk, 
when the pre-market scenario is scaled up to 
the extensive commercial operations, all 
measures of containment and risk mitigation 
become questionable. Indeed, in the event of 
a final approval, AquaBounty plans on selling 
the GE sterilized eggs to ad hoc contained, in-
land facilities in the US territory and Canada, 
supposedly equipped with the same complex, 
expensive system of barriers. Given the 
significant numbers of fish raised in such a 
large-scale industrial production system, 
                                                 
11
 The FDA did examine the likelihood of GE salmon 
escaping (i.e. probability of exposure), but did not 
extensively analyze the environmental consequences 
if salmon did escape (i.e. harm, given the exposure to 
the hazard). The quality of the expertise of the US 
Agency has been highly contested, together with the 
failure to adequately consult with other US 
government agencies with the required expertise (US 
Senate Subcommittee on Ocean, Atmosphere, 
Fisheries and Coast Guard Oversight 2011). 
even a very low but non zero probability of 
accident, inherent in any system of barriers 
(Guarnieri et al. 2008), would end up 
amounting to a significant risk of GE salmon 
escape, drastically raising up the probability 
of exposure.  
2.3.4 Human health implications and material 
equivalence  
As we have mentioned, the AquAdvantage 
Salmon is the first genetically modified 
animal designed for human consumption. The 
issue of its health implication is thus 
absolutely new and, for this reason, 
independent, systematic studies about food 
safety do not yet exist. The matters of concern 
are two-fold: (1) allergenicity, and (2) the 
undesired modification of the biochemical 
composition of the edible tissues due to the 
alteration of metabolic processes. 
The Atlantic salmon in itself is a known 
allergenic food, thus it is probable that the 
AquAdvantage Salmon is also as such. ABT 
claims to have conducted studies on its 
allergenicity, but they were considered as 
unsatisfactory by the CVM-FDA. The CVM-
FDA have since conducted their own studies 
on the allergenic potential of triploid salmon 
expressing the EO-1α gene, which did not 
result as being different from that of controls 
(VMAC 2010).  
ABT declares to have carried out analyses on 
the principal biochemical components of the 
edible tissues of the salmon (carbohydrates, 
proteins, total fats, vitamins and minerals) 
without finding any significant variations, 
with the only exception of a slight increase in 
the concentration of vitamin B6 in the 
AquAdvantage Salmon (0.77 mg/g of tissue), 
which anyway remains lower than that found 
in other edible fish, such as tuna (0.8 mg/g). 
However, the most important problem could 
be the increased hormone content of the 
edible tissues of the AquAdvantage Salmon. In 
particular, the higher concentration of 
insulin-like growth factor-1 (IGF-1) gives rise 
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to concern: 10.26 ng/g in AquAdvantage 
Salmon compared to 7.34 ng/g in wild 
Atlantic salmon. IGF-1 in salmon, though 
being relatively different to the human 
version (35/141 amino acids are different), 
could conserve significant biological activity. 
IGF is a strong stimulator of cell proliferation 
and its production by specific types of 
hepatocyte depends directly on the activity of 
GH (Giovannucci et al. 2003). According to 
Bodnar (2010), salmon IGF-1 is 2-3 times less 
effective at binding human IGF-1 receptors 
compared to mammal IGF-1. But these are 
very approximate data. The conditions of 
these evaluations are not indicated and the 
receptor-hormone affinities in very different 
species is not explored. As IGF-1 represents a 
critical issue, it is unsettling that the FDA 
hasn’t conducted a complete analysis in order 
to evaluate on the one hand the actual 
concentration of IGF-1 in edible tissues of the 
AquAdavantage salmon, on the other the 
binding affinity with the human IGF-1 
receptor (McEvilly 2013).  
In addition, as we have seen regarding the 
biochemical alterations caused by 
deregulated GH expression, the study of the 
possible health implications cannot be limited 
to the analysis of the direct effect of the 
transgene action (VMAC 2010), nor to the 
study of allergens (Van Eennemann and Muir 
2011) but has to be extended to the direct 
and indirect effects on the entire cell 
metabolic network.  
In conclusion, from what we have explored so 
far, the assessment of environment and 
health implications is fragmented and 
incomplete within the regulatory framing of 
the FDA. However, even more radically, it is 
also inherently limited by the choice the 
framing. The health risks are quantified by 
FDA by comparing the nutritional profile of a 
GE salmon to a non-GE salmon and screening 
for toxins and allergens, in order to evaluate 
if the transgenic fish is “materially 
equivalent” to the non-transgenic one. This 
quite restrictive approach, which doesn’t 
consider the environmental issues per se, 
derives from the fact that the transgenic 
animals are regulated as veterinary drugs and 
not as food. Indeed, according to US 
regulatory processes12, the transfer of genetic 
information can be viewed as a way to deliver 
a drug (hormone, protein, etc.) to the tissue of 
the animal. In the case of the AquaBounty’s 
transgenic fish, the ocean pout promoter gene 
is considered as a drug delivering growth 
hormones to the tissues of the fish. Moreover, 
only an abstract pre-market scenario is 
analyzed, leaving aside the considerable 
possible larger-scale, irreversible 
implications of the actual GE salmon 
commercialization (Bratspies 2008, Smith 
2010).  
Overall, in this highly reductionist 
framework, the complexity of the interaction 
between the transgenic fish and the network 
of ecological, economical, social and cultural 
systems it depends upon, is not 
acknowledged. 
3. GE salmon and the narrative of 
innovation: optimization and 
substitution 
With this overall picture in mind, let’s now 
shift our attention to the driving forces that 
have brought into existence the 
AquAdvantage salmon, and the current legal, 
scientific and regulatory controversy around 
it13.  
                                                 
12
 The United States has decided to regulate 
transgenic animals under the Food and Drug Act’s 




 A full account of the controversy around the 
commercialization of AquAdvantage salmon is 
beyond the scope of this work. We provide here an 
overview by listing the main stakeholders involved 
and referring to a few articles in journals and mass 
media for some details: 1) ABT, trying to financially 
survive and move forward its business plan (Pollack 
2012b); 2) FDA, slowly progressing in the regulation 
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As we have mentioned, the motives behind 
the research, production and possible 
commercialization of the transgenic fish can 
be regarded as belonging to a grand narrative 
of technoscientific innovation, defined as the 
engine of economic, social and environmental 
wealth, and a way out of our contemporary 
systemic crisis (European Commission 2010 
and 2011). 
3.1. The narrative of innovation and the 
commoditization of food 
The dominant discourse about innovation is 
invoked as a solution for sustaining our 
accelerating increase of global resource 
consumption within a single planet, i.e. a 
complex, closed and finite system, with 
limited stocks and bio-geo-chemical 
resilience (Rockström et al. 2009). The way 
out of this paradoxical dynamic is to rely on 
the (unlimited) human creativity, in order to 
decouple growth from scarcity, optimizing 
the use of natural resources and ultimately 
substituting them altogether, with 
substantially equivalent, technological 
optimized artifacts. At the same time, in the 
narrative of innovation, the human power to 
enhance socio-ecological systems has to be 
applied to treat the possible negative 
outcomes as they arise, taming complexity, 
uncertainty and the risks of failures through 
                                                                         
process (Pollack 2010) 3) the government of Canada 
and Panama addressing regulatory and economic 
issues (Goldenberg 2013, Colwell 2015); 3) US 
Senate and Congress, Obama administration (United 
States Senate 2013, Congress of Representatives 
2013, Goldenberg 2013, Entine 2011); 4) US 
aquaculture industry (Joy 2010); 5) other nations 
expressing the interests of their aquaculture industry 
(Development Fund 2013); 6) the animal 
biotechnologists and the biotech industry (Prakash et 
al. 2012, Muir 2013 and Roberts et. al.2014); 6) food 
related NGOs (http://www.centerforfoodsafety.org 
http://www.foodandwaterwatch.org  see for example 
Larsen 2014) 7) the US retailers and consumers 




the implementation of effective ad hoc 
technoscientific silver bullets.  
Moreover, innovation is taken as the 
mainstream solution in order to keep 
sustaining growth in a hyper-saturated 
market, by opening up new pathways of 
competitiveness and consumption, to be filled 
with new, constantly upgraded and more 
seductive products and services.  
Finally, in order for the whole narrative to be 
functional, a fundamental condition has to be 
met: citizens of developing, developed and 
declining economies have to value and 
ultimately buy - both metaphorically and 
literally – the processes and products of 
technoscientific innovation. This means that 
the societal expectations about the goods 
have to be encouraged and the concerns 
about the bads deflected (EC 2013). 
In terms of food production, this narrative 
was first at work in the 60s, with the wonders 
of the “Green Revolution”: the prospect to 
intensify and optimize the process of 
agriculture and farming through the use of 
chemical and mechanical technologies, all 
based on fossil fuels. With the 
industrialization of the production system 
and the ability to accumulate a significant 
surplus, the commodification of food became 
possible. As a result of this process, food 
began to be considered for its exchange-value 
first, and its use-value only second (Araghi 
2003). The ideal of technological power as a 
way to provide food security and at the same 
time economic growth was then established. 
Production efficiency had to be indefinitely 
increased in order for industries to continue 
growing and rising return of investments: the 
combination of selective breeding, fertilizers 
and pesticides became essential for the whole 
system to be functional. This focus on 
optimization necessarily externalized 
environmental degradation and ecosystems 
disruption, and fostered the idea that natural 
resources could be substituted with 
technologically enhanced products. 
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In early nineties, with the globalization of 
food markets, this transition was deepened 
by a number of factors, including the 
decoupling of animal farming from land 
(Naylor et al. 2005) and the onset of genetic 
engineering into the agri-food industry 
(Jasanoff 2005). With the so-called “Gene 
Revolution”, biotechnology monopolized the 
scene of technoscientific innovation for food 
production, with the promise of boosting 
yields and reducing production costs and 
environmental impacts, thus ensuring – again 
– both higher profits and food security for a 
growing population. This further move 
towards the commodification of food 
consisted on the possibility to transform the 
conventional practice of selective breeding 
into an invention – through direct genetic 
manipulation – that could be patented, just 
like any other technological breakthrough. In 
the late nineties, this further technoscientific 
move encountered the opposition of citizens 
and governments, especially within the 
European Union, for a combination of 
environmental, health and economic 
concerns (Jasanoff 2005). In a quite 
unanticipated scenario, the biotech industry 
had to develop a whole new set of positive 
narratives, in order to balance the resistance 
of both investors and consumers (Benessia 
and Barbiero 2012): once again, the urgent 
need to feed a fast growing global population, 
then the necessity to adapt to and even 
mitigate climate change, and finally the 
possibility of limiting the use of chemical and 
pesticides. These were developed then as 
main arguments in favor of a transition to a 
genetically engineered agriculture system.  
Around the same time and within the same 
context, the farming of aquatic organisms in 
controlled environments became a global 
industry, supplementing the declining supply 
of fisheries and increasing the global fish 
market. In perfect analogy with industrial 
agriculture and farming, the ideal of the “Blue 
Revolution” is to use technology to maximize 
productivity by reducing unpredictability – in 
this case of harvesting fish – and boosting the 
efficiency of animal growth and feed-to-
biomass ratio through selective breeding.  
A new “food regime” was then in place, where 
animal proteins produced with feed from a 
variety of nations were channeled into 
consolidated food chains to supply privileged 
consumers with fresh meat and fish 
(McMichael 2009).  
As we have seen, in the same years, a US 
aquaculture industry named E/F Protein 
developed and patented a fast-growing fish 
called AquAdvantage salmon. The US Food 
and Drug Administration was then appointed 
to regulate its possible commercialization for 
human consumption. 
3.2 The salmon industry: optimization and 
substitution  
Today, approximately half of all fish 
consumed by humans is raised on farms and 
modern industrial salmon aquaculture is 
among the most relevant and profitable form 
of fish farming (FAO 2014). The recent 
history of the relationship between human 
beings and salmon follows a common pattern 
of over-exploitation and environmental 
degradation, leading to a major decline in the 
wild fish populations, both in the Atlantic and 
the Pacific rivers and oceans (Greenberg 
2010). Like with other natural resources, we 
are facing the paradox of a required 
production growth within a regime of 
increasing scarcity. The majority of the 
world’s fisheries are either fully exploited, 
overexploited, or depleted. It is estimated 
“that the global ocean has lost more than 90% 
of large predatory fishes” since the pre-
industrial level (Meyers and Worm 2003). 
In the framing of innovation, the growing 
demand of seafood is driven by consumption 
needs, caused population growth and a 
legitimate call for healthier sources of animal 
proteins, leading to the necessity of 
producing more fish for the global market. On 
the other hand, scarcity of salmon resources 
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is due to overfishing and habitat depletion. 
The solution to this conundrum consists on a 
number of technological fixes, enacted both 
as conservation measures and production 
boosts. These innovations are founded on two 
fundamental principles: optimization and 
substitution. The first is the ideal that the 
efficiency of production can be increased 
more or less indefinitely, through a 
progressive reduction of the matter, energy 
and time involved in the process. This is only 
possible if a second assumption is considered, 
i.e. that natural resources can be substituted 
with technologically enhanced artifacts. In 
our case, the ecological and biological 
characteristics of salmon can and have to be 
altered so that they no longer require free-
flowing clean rivers for spawning and 
reproduction, and entire seasons in the ocean 
for predating and maturing.  
In their recent studies on fisheries and 
aquaculture, US environmental sociologists 
Clausen, Longo and Clark (2012, 2014 and 
2015) provide a compelling historical and 
socio-economic analysis of these 
technoscientific fixes on wild salmon, 
essentially structured in three phases: 
hatchery enhancement, conventional fish 
farming and genetic engineered inland 
aquaculture. In our context, each phase 
corresponds to the substitution of a 
component of salmon lifecycle, in order to 
keep optimizing the production process and 
increasing its output, in spite of 
environmental degradation and ocean 
depletion. 
The first hatchery-enhancement policies, 
introduced in the late nineteen century in 
Basin Columbia, aimed at supplementing wild 
population to increase the number of salmon 
that could be sold on the market, while 
mitigating the effect of salmon habitat 
degradation. At that time, the migratory 
rivers were progressively covered with dams 
to supply with hydroelectric power the 
raising industries and irrigation-intensive 
farms, and the clean, oxygenated watersheds 
were polluted by agricultural run-off and 
industrial waste (Lichatowicz 1999). Salmon 
could no longer reach their natural spawning 
grounds and the technical solution was to 
substitute natural with artificial spawning: 
fish managers could extract the eggs and milt 
from salmon brook stock, mix their genetic 
material and raise the fertilized eggs in closed 
containers. Once the salmon grew enough in 
the hatchery, they would be released into 
selected streams and allowed to reach the 
oceans. This technological fix introduced the 
issue of genetic pollution: the genetic traits 
selected to optimize the salmon’s early life in 
the hatchery environment decreased their 
fitness in natural environment. As they were 
interbreeding with wild salmon, they ended 
up weakening the overall population and 
paradoxically contributing to its further 
decline. In other words, the substitution had a 
cost.  
The next stage in the process of optimization 
was the introduction of salmon farming, 
which expanded in the global market in the 
early 1980s. In this case, the entire migration 
process is eliminated and salmon remain in 
captivity for their whole lifecycle. The young 
smolts14 are transferred from the hatchery 
were they were born to net pens or cages 
suspended in coastal marine waters, where 
they are artificially fed and allowed to grow 
until right before sexual maturity. At that 
time, they are harvested and sold.  
By compensating and ideally substituting 
traditional fishery in the global market, this 
innovation is meant to eliminate the need to 
regulate harvest and protect or restore 
salmon habitat. Moreover, this optimization 
process allows producing fresh salmon all 
year around, of uniform size and features. In 
analogy with industrial agriculture and 
farming, conformity and predictability 
substitute variety and seasonality.  Moreover, 
as the industrialization process is complete, 
                                                 
14
 The young salmon are called smolts when they are 
ready to live in saltwater. 
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the energy, matter and time required to 
produce one salmon can and have to be 
optimized: through selective breeding, 
photoperiod and water temperature 
manipulation, mechanized and high 
performance feeding. The costs of this 
substitution, namely the physiological, 
environmental and ecological drawbacks – 
such as infectious salmon anemia (ISA) 
outbreaks, sea lice infestations, water and 
genetic pollution  ¬– are supposedly 
controlled and treated through more fixes 
and containment measures, or simply 
externalized (Lymbery 2002). Moreover, as 
the natural ratio between big predators - such 
as salmon - and the small fish they eat is 
broken, a new resource scarcity issue has to 
be solved. Small fisheries and the fish oil 
derived from them, fundamental for intensive 
aquaculture feed, are rapidly declining.  
In this framework, salmon is conceived and 
valued as a commodity for global markets, 
requiring constant growth and returns on 
investments, rather than as a nutritional food 
source and a component in an ecosystem. 
Interestingly though, in order for the whole 
system to be functional, as we have 
mentioned, people have to value farmed 
salmon in order to buy them, and they are 
certainly more inclined to do it if they identify 
them as a source of healthy and 
environmentally friendly food, than as an 
industrially optimized commodity. Hence the 
inherent ambivalence of the whole narrative 
of innovation: For investors, salmon farming 
is the best solution for optimizing the 
production process and boosting productivity 
and profits. For consumers, salmon farming is 
meant to fix the issue of wild fish population 
decline, while feeding a growing human 
population with a healthy and cheap source 
of animal proteins. This is the ideal and 
controversial win-win scenario of sustainable 
growth (Benessia and Funtowicz 2015): one 
interesting open question in this regard is if 
the actual demand of seafood is driven by 
production (i.e. need for economic growth) or 
consumption (i.e. actual need for food). From 
what we have seen, in the current “third food 
regime”, the former is a far more likely 
candidate for an answer than the latter.  
In this overall context, the idea of producing a 
genetically modified, fast-growing salmon for 
human consumption becomes perfectly 
understandable and not novel at all, as 
belonging to the same path-dependent 
trajectory of innovation. The narrative 
associated with the product of AquaBounty 
follows the lines of the previous technologies: 
For the consumers, it is meant to address the 
issue of global hunger and provide healthy 
and cheap animal proteins (Smith et al. 
2010), while tackling the problem of fishery 
depletion (the first level of environmental 
cost of the industrialization process). 
Moreover, it promises to fix the ecological 
consequences of the technology it is supposed 
to replace, namely the environmental 
pressure of conventional aquaculture (the 
second level of environmental costs). For the 
investors, transgenic salmon aquaculture is 
meant to further lower the budget of 
production, by improving productivity and 
profit shares15.  
All this is proposed at the price of a new kind 
of substitution, within the salmon’s own 
physiology. The idea is to push the 
optimization process one step further by 
enhancing the fish metabolism so that it 
requires even less time, space and matter to 
grow to market size. What was originally a 
wild fish is substituted with a 
technoscientific, patented invention16. As we 
have explored in the first part of our work, 
once again, this substitution has an inherent 
cost, represented by the higher stakes in 
                                                 
15
 This aspect is controversial, as it depends on the 
amount of licensing fees for the patented eggs and the 
cost of the environmental conditions and the 




 The AquAdvantage salmon was defined as one of 
ten best inventions of 2010 by Times magazine 
(Walsh 2010). 
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terms of public and private investments, 
health and environmental risks.  
Finally, given the resistance of both potential 
consumers and investors (Kelso 2003), a new 
set of arguments is added to the narrative, 
mainly directed to regulators and based on 
the political economy of food, namely the 
global competition for market shares. First, as 
a major innovation in the homeland industry 
of fish farming, the production of transgenic 
salmon is aimed at bridging the gap of the US 
seafood trade deficit (Forristall 2014). 
Second, a refusal or even a delay in the 
approval of the new technology could create a 
possible competitive disadvantage with other 
countries eventually ahead in the business of 
transgenic animal food (Maxmen 2012, Van 
Eenennaam in Watson 2013).  
The AquAdvantage salmon can then be 
interpreted as the tip of the iceberg of a 
global, fully commodified food production 
system whose dynamic is constrained within 
the path-dependent trajectory of innovation. 
However, as the stalling FDA regulatory 
status manifests, the emergent complexity 
and radical uncertainty of this open-field 
experimentation challenge its inevitability 
and open up a democratic space of discussion.    
We devote our concluding remarks to explore 
how. 
4. Concluding remarks: evaluating 
the quality of (GE) salmon 
As we have mentioned, the whole narrative of 
innovation can only be functional if the 
citizens and potential consumers value and 
ultimately buy the products of the emergent 
technologies. This means that the societal 
expectations about the goods have to be 
encouraged and the concerns about the bads 
deflected. The set of arguments that we have 
reviewed so far have precisely this function. 
However, the ultimate fate of a new 
technology fundamentally depends on 
identifying what the goods and the bads 
actually are and for whom, at any given time. 
This recognition has to do with how the 
product of technoscientific innovation is 
valued, therefore with its quality. 
Failing to acknowledge the quality criteria of 
potential consumers and investors can be 
lethal, and it is at the heart of the so-called 
“Concorde syndrome” (Giampietro 2009). 
The Concorde syndrome occurs when the 
framing of the problem to be solved and 
therefore the technoscientific tools provided 
to address it, are obsolete with respect to the 
actual social perception of what the needs to 
be fulfilled are. In the case of the legendary 
airplane, the problem to be solved was to 
build a supersonic commercial aircraft that 
could fly much faster than all its competitors 
– as a matter of fact twice as fast – so as to 
become the preferred carrier for both 
investors and customers. However, the 
Concorde was permanently dismantled in 
2003, and not because it was more risky or 
environmentally harmful, but because the 
actual flying time did not prove to be a critical 
factor for choosing it, and the global aviation 
industry ended up privileging slower, time 
flexible and cost effective flight systems.  
In our case, the application of genetic 
engineering to commercial aquaculture in 
order to further optimize production rates 
and profits might end up being a failure, 
independently of the outcome of the 
regulation process, for two orders of reasons.  
The first is more pragmatic: the overall 
limited potential economic gain of transgenic 
aquaculture (still to be demonstrated) might 
not justify switching to a new costly, risky 
and highly secured technology from 
conventional aquaculture practices. 
Moreover, the selectively bred salmon 
industry might boycotting it, fearing that the 
public perception of transgenic fish as 
environmentally risky would increase the 
social controversy and conflict surrounding 
its practice in the US and Canada, making the 
industry expansion more difficult.  
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The second order of reasons is more radical: 
it might well be that this ultimate 
technoscientific substitution process 
stretches excessively the definition of what a 
salmon is, possibly tearing apart the very 
texture of the space in which the trajectory of 
innovation moves along. The framing of food 
as a commodity entails the application of the 
principle of substantial equivalence, at the 
foundation of FDA’s impact assessment 
procedure. This means that independently 
from their taste, texture, smell, cultural 
traditions and above all, independently of the 
process by which they are produced, food 
products with essentially the same nutritional 
components are assigned to the same 
category, and have all the same quality. In this 
framing, wild Atlantic salmon is equivalent to 
farmed Atlantic salmon, and the latter is in 
turn equivalent to the transgenic 
AquAdvantage salmon. It might well be that 
this equivalence breaks down on the shelf of 
grocery stores and on the tables of US 
consumers17, and not necessarily only for 
(more or less scientifically-based) health or 
environmental fears, but also because they 
simply don’t identify the farmed (GE) salmon 
as valuable food18. 
                                                 
17
 In September 2010, a US public survey 
commissioned by the Center for Food Safety showed 
that 91% of Americans opposed the 
commercialization of genetically engineered fish and 
meat into the market place, 83% of which strongly so 
(Lake Research 2010). Around the same time, more 
than 60% of readers of the conservative Wall Street 
Journal declared that they wouldn’t eat the transgenic 
salmon (Wall Street Journal 2010). In 2013, the FDA 
public hearing period after the release of the GE 
salmon environmental assessment ended with 1,8 
million of comments against the approval. 
Meanwhile, since 2002 some of the main US retailers 
such as Trader Joes, Whole Foods, Alti and Marsh, 
joined by a number of US chefs and grocers publicly 
declared that in case of approval they would not sell 
the GE salmon (Burros 2002). 
 
18
 The issue of the labeling of GE salmon is still 
unresolved, although an overwhelmingly 93% of US 
consumers are in favor (Thomson Reuters 2010). The 
Indeed, the public’s health and environmental 
concerns are shaped only in part by the 
scientific/technical information developed 
within regulatory impact assessments. More 
fundamentally, they emerge from inherently 
political issues about what risks are 
acceptable under what circumstances, and 
about how to evaluate the food they eat. If we 
unlock the framing of innovation at its roots, 
we may find a collective democratic space for 
discussing different quality criteria, based for 
example on the use-value of food, the 
inherent socio-ecological value of a species 
and of the entire landscape it depends upon. 
More generally, the question becomes: how 
many categories are needed to describe our 
food and who decides about the definitions to 
be adopted for the various categories? 
This reflective awareness triggers the 
possibility of exploring alternative 
trajectories for our food production system 
and redefining the quality assessment criteria 
for its evaluation. Robust and resilient 
innovations can only emerge from opening up 
the collective space of options for both the 
framing of the problems to be solved and the 
tools proposed to solve them.  
In our case, even if we keep the framing of the 
problem proposed by ABT, namely the 
growing population and demand of salmon, 
the decline of the wild population and the 
environmental and health drawbacks of 
open-water net-pen aquaculture, then 
transgenic salmon are not the only available 
option. A plurality of strategies and tools can 
be considered. The Arctic char, a close 
relative of the Atlantic salmon, is already 
being grown nearly exclusively in closed 
containment facilities and requires no genetic 
modification. Its taste is comparable to the 
one of farmed salmon and, given its size and 
texture, it performs all the culinary functions 
                                                                         
resistance from ABT and in general from the biotech 
industry indicates the relevance of the consumers’ 
quality assessment criteria. 
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of its comparator19 (Greenberg 2010a). 
Furthermore, a closed-containment-grown 
Coho salmon that is not genetically modified 
is now in production and has been evaluated 
as "best choice" by the Monterey Bay 
Aquarium's Seafood Watch20 (Greenberg 
2010b). Finally, a promising experiment of 
closed-containment, ecologically friendly, non 
transgenic, fast growing Atlantic salmon 
aquaculture is undertaken in the Northeast 
corner of Canada’s Vancouver Island, by the 
‘Namgis First Nation, under the name of 
Kunterra project (Sitlts 2014).  
If, on the other hand, we question the framing 
itself, then we can argue that the actual 
demand for salmon could be reduced and 
balanced by incorporating into our food 
habits a variety of seafood products, including 
smaller fish, and an even larger diversity of 
animal and vegetal proteins, depending on 
our culturally, historically and geographically 
based food tradition. Moreover, the very old, 
artificial separation between the problem of 
the wild salmon decline and the preservation 
of its socio-ecological habitat could be 
removed.  
A project like the Pebble copper, gold an 
molybdenum mine proposed for Bristol Bay 
in Alaska, could wipe out the most abundant 
and productive sockeye salmon grounds in 
the world—an annual run of 40 million fish21. 
If we fully embrace the dominant narrative of 
innovation and the principle of substantial 
equivalence, then this sanctuary of wild 
salmon and traditional fishery practice could 
be substituted by a number of aquaculture 
(transgenic or non-transgenic) farms, 
conveniently dislocated in areas where they 
don’t conflict with the mining operations. The 
                                                 
19







 For more details, see 
http://www.savebristolbay.org/about-the-bay/about-pebble-
mine 
win-win scenario would then be having the 
same or larger amount of salmon per year 
and foster the economic growth of both the 
mining and the aquaculture industry. On the 
other hand, if we question the dominant 
narrative of innovation and we apply 
different quality assessment criteria based on 
community and ecological needs, then the 
whole idea of destructing one of the few 
preserved habitats for wild salmon and for all 
the socio-ecological systems involved, 
becomes untenable22.  
In conclusion, opening up a democratic space 
for evaluating the quality of innovation 
means being able, with time and imagination, 
to explore the controversies and conflicts 
emerging within its dominant trajectory, 
questioning not only the technologies 
involved, with their future risks and 
promises, but also and most importantly, the 
driving forces that might bring them – or not 
– into the world today. 
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